The stock of Immunomedics, Inc. (NASDAQ:IMMU) is a huge mover today! About 2.96 million shares traded hands or 90.97% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 2.88% since March 3, 2016 and is uptrending. It has underperformed by 5.46% the S&P500.
The move comes after 9 months positive chart setup for the $186.69M company. It was reported on Oct, 6 by Barchart.com. We have $7.35 PT which if reached, will make NASDAQ:IMMU worth $349.11M more.
Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage
Out of 2 analysts covering Immunomedics (NASDAQ:IMMU), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Immunomedics has been the topic of 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Jefferies upgraded Immunomedics, Inc. (NASDAQ:IMMU) rating on Friday, May 6. Jefferies has “Buy” rating and $5 price target. As per Wednesday, July 29, the company rating was downgraded by Jefferies. On Friday, December 4 the stock rating was downgraded by Wells Fargo to “Market Perform”. The firm earned “Hold” rating on Tuesday, March 15 by Jefferies. The firm earned “Market Perform” rating on Tuesday, June 21 by Wells Fargo.
According to Zacks Investment Research, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.09, from 1.11 in 2016Q1. The ratio fall, as 14 funds sold all Immunomedics, Inc. shares owned while 34 reduced positions. 27 funds bought stakes while 22 increased positions. They now own 50.90 million shares or 5.47% more from 48.26 million shares in 2016Q1.
Blackrock Institutional Trust Na, a California-based fund reported 2.68M shares. Grp Inc reported 50,237 shares or 0% of all its holdings. Ladenburg Thalmann Services Incorporated accumulated 0% or 200 shares. Gp One Trading Ltd Partnership, a Illinois-based fund reported 462,247 shares. Proshare Advsrs Limited Co has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). New York State Common Retirement Fund accumulated 0% or 87,900 shares. State Board Of Administration Of Florida Retirement accumulated 93,107 shares or 0% of the stock. Swiss Savings Bank has 0% invested in the company for 145,450 shares. State Street, a Massachusetts-based fund reported 2.35M shares. D E Shaw holds 18,800 shares or 0% of its portfolio. Raymond James Svcs has 0% invested in the company for 23,776 shares. Geneva Advisors Limited Liability Company accumulated 33,935 shares or 0% of the stock. Price T Rowe Inc Md has 33,100 shares for 0% of their US portfolio. Parametric Port Assoc Llc has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Moreover, Bailard has 0.09% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 315,000 shares.
Insider Transactions: Since June 6, 2016, the stock had 0 insider purchases, and 7 insider sales for $5.11 million net activity. 371,990 shares with value of $1.13M were sold by GOLDENBERG CYNTHIA L on Friday, June 10. 371,990 shares were sold by GOLDENBERG DAVID M, worth $1.13 million. Shares for $29,451 were sold by Stark Don C on Wednesday, August 24. PAETZOLD MARY E sold $44,673 worth of stock or 15,000 shares. $44,634 worth of Immunomedics, Inc. (NASDAQ:IMMU) shares were sold by MARKISON BRIAN A.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.